Pharmacokinetics of Posaconazole Given as a Single Intravenous Dose to Obese Subjects: Dosing Obese With Noxafil Under a Trial (DONUT)
Latest Information Update: 13 May 2022
At a glance
- Drugs Posaconazole (Primary)
- Indications Candidiasis; Chagas disease; Invasive bronchopulmonary aspergillosis; Mycoses; Oropharyngeal candidiasis
- Focus Pharmacokinetics
- Acronyms DONUT
- 23 Jan 2020 Primary endpoint Posaconazole exposure (AUC0-24h) has been met as per results published in the Journal of Antimicrobial Chemotherapy
- 23 Jan 2020 Results published in the Journal of Antimicrobial Chemotherapy
- 16 Apr 2019 Results (n=24) presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases.